- Investing.com
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
Metrics to compare | ALKb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALKbPeersSector | |
---|---|---|---|---|
P/E Ratio | 53.5x | −0.5x | −0.6x | |
PEG Ratio | 0.54 | 0.02 | 0.00 | |
Price/Book | 7.5x | 2.5x | 2.6x | |
Price / LTM Sales | 7.1x | 4.9x | 3.2x | |
Upside (Analyst Target) | 3.0% | 22.8% | 48.4% | |
Fair Value Upside | Unlock | 5.5% | 6.8% | Unlock |